If you take Ozempic, Wegovy, Mounjaro or another GLP-1 medication, a new eye-safety warning may have caught your attention. Here’s what changed, what symptoms deserve immediate attention, and what to discuss with your prescribing clinician.
What changed on November 9?
The FDA announced that it is requiring GLP-1 medication labeling to warn about a potential increased risk of NAION, a rare but serious eye condition. This is a required safety-label update, not a recall.
The FDA reviewed a small number of cases in clinical trials along with other evidence. The warning identifies a potential risk; it does not mean everyone taking these medications will develop the condition. Read the FDA announcement.
What is NAION?
NAION stands for non-arteritic anterior ischemic optic neuropathy. In plain language, blood flow to the front of the optic nerve becomes insufficient. That nerve carries visual information from the eye to the brain.
NAION usually causes sudden, painless vision loss in one eye. Someone might notice a gray or dark area, a missing section of vision, or significant blur. The damage can be permanent.
Other factors, including diabetes, high blood pressure, sleep apnea and the structure of the optic nerve, can also be associated with NAION. Evaluating someone’s risk therefore requires more than looking at one medication. Learn more from NANOS.
Which symptoms should not wait?
Sudden vision loss, a new blind spot or missing area of vision, distorted colors, or a sudden reduction in sharpness needs prompt medical attention, even without pain. Contact an eye-care professional immediately rather than waiting for a routine appointment. If prompt eye care is unavailable, seek emergency evaluation.
Don’t change your medication on your own because of a headline. Discuss the warning with your prescriber, particularly if you have previously had NAION. FDA guidance for patients.
A useful conversation to have
At your next nonurgent visit, consider asking:
Does this warning change the balance of benefits and risks for me?
Does my eye history affect that discussion?
Who should I contact if I develop sudden vision changes?
Bring an updated medication list and mention any previous diagnosis of NAION. A routine appointment is a good place for questions, but it is not a substitute for urgent evaluation of new symptoms.
My advice is to take this warning seriously without letting a headline make your treatment decision for you. Know the symptoms, keep your eye-care team and prescriber informed, and make medication decisions together. Remember, no medications are risk free and while the risk of NAION is not zero it is still very small. Considering the long term benefits, these medications still have an important role in healthcare and decisions about them should be in consultation with your entire healthcare team.